ASX Growth Companies With High Insider Ownership And At Least 11% Revenue Growth
Reviewed by Simply Wall St
Amidst a somewhat directionless Australian market, with the ASX200 showing minimal movement and commodities experiencing varied trends, investors continue to seek opportunities that stand out from broader market fluctuations. In this context, growth companies with high insider ownership can be particularly appealing as they often signal strong confidence from those closest to the company’s operations and future prospects.
Top 10 Growth Companies With High Insider Ownership In Australia
| Name | Insider Ownership | Earnings Growth |
| Hartshead Resources (ASX:HHR) | 13.9% | 86.3% |
| Cettire (ASX:CTT) | 28.7% | 30.1% |
| Acrux (ASX:ACR) | 14.6% | 115.3% |
| Doctor Care Anywhere Group (ASX:DOC) | 28.4% | 96.4% |
| Plenti Group (ASX:PLT) | 12.8% | 106.4% |
| Hillgrove Resources (ASX:HGO) | 10.4% | 45.4% |
| Change Financial (ASX:CCA) | 26.6% | 85.4% |
| Botanix Pharmaceuticals (ASX:BOT) | 11.4% | 120.9% |
| Liontown Resources (ASX:LTR) | 16.4% | 63.9% |
| SiteMinder (ASX:SDR) | 11.3% | 72.7% |
Let's review some notable picks from our screened stocks.
Botanix Pharmaceuticals (ASX:BOT)
Simply Wall St Growth Rating: ★★★★★★
Overview: Botanix Pharmaceuticals Limited, based in Australia, focuses on the research and development of dermatology and antimicrobial products with a market capitalization of approximately A$519.80 million.
Operations: The company generates revenue primarily from its research and development activities in dermatology and antimicrobial products, totaling approximately A$0.44 million.
Insider Ownership: 11.4%
Revenue Growth Forecast: 120.4% p.a.
Botanix Pharmaceuticals, with a modest A$437K in revenue, is poised for significant expansion. The company's Return on Equity is expected to be very high at 43.9% in three years, complemented by a projected annual earnings growth rate of 120.89%. Despite these promising figures, Botanix faces challenges such as less than one year of cash runway and recent shareholder dilution. On May 6, 2024, the firm discussed its commercial launch plans for SofdraÔ as it nears approval.
- Dive into the specifics of Botanix Pharmaceuticals here with our thorough growth forecast report.
- According our valuation report, there's an indication that Botanix Pharmaceuticals' share price might be on the expensive side.
Capricorn Metals (ASX:CMM)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Capricorn Metals Ltd is an Australian company focused on the evaluation, exploration, development, and production of gold properties, with a market capitalization of approximately A$1.77 billion.
Operations: The company generates revenue primarily from its Karlawinda segment, totaling approximately A$356.94 million.
Insider Ownership: 12.3%
Revenue Growth Forecast: 14.1% p.a.
Capricorn Metals is set to outpace the Australian market with its revenue and earnings growth forecasted at 14.1% and 26.5% per year, respectively. Despite a lack of recent insider buying and significant one-off items affecting its financial results, the company's Return on Equity is expected to reach a high of 30.6% in three years. However, it faces challenges as profit margins have decreased from last year's 25.4% to just 5.2%.
- Take a closer look at Capricorn Metals' potential here in our earnings growth report.
- The valuation report we've compiled suggests that Capricorn Metals' current price could be inflated.
Technology One (ASX:TNE)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Technology One Limited is an Australian company that develops, markets, sells, implements, and supports integrated enterprise business software solutions both domestically and internationally, with a market capitalization of A$5.97 billion.
Operations: The company generates revenue through three primary segments: software sales contributing A$317.24 million, corporate services at A$83.83 million, and consulting services totaling A$68.13 million.
Insider Ownership: 12.3%
Revenue Growth Forecast: 11.1% p.a.
Technology One, an Australian software company, shows promise with its insider ownership structure supporting a growth narrative. The company's revenue and earnings are forecasted to grow at 11.1% and 14.3% per year respectively, outpacing the broader Australian market rates of 5.4% and 13.7%. Although this growth is robust, it does not reach the high-growth benchmark of over 20%. Recent financials underscore this trajectory with a reported increase in half-year revenue to A$240.83 million from A$201.01 million year-on-year and net income rising to A$48 million from A$41.28 million.
- Click here to discover the nuances of Technology One with our detailed analytical future growth report.
- Our expertly prepared valuation report Technology One implies its share price may be too high.
Key Takeaways
- Delve into our full catalog of 91 Fast Growing ASX Companies With High Insider Ownership here.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Contemplating Other Strategies?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Botanix Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About ASX:BOT
Botanix Pharmaceuticals
Engages in the research and development of dermatology and antimicrobial products in Australia and the United States.
Exceptional growth potential with excellent balance sheet.
